Overview

• Levi & Korsinsky and Rosen Law Firm are notifying Unicycive Therapeutics shareholders about a pending securities class action and the upcoming lead‑plaintiff deadline.
• The putative class covers purchases of Unicycive securities from March 29, 2024 through June 27, 2025.
• The complaint claims the company overstated its readiness to meet FDA cGMP requirements and overstated the regulatory prospects of the oxylanthanum carbonate NDA.
• Plaintiffs point to June 2025 disclosures, including FDA-identified cGMP deficiencies at a third‑party subcontractor and a subsequent Complete Response Letter, as the events that triggered losses.
• No class has been certified, and firms say investors may participate on a contingency basis without out‑of‑pocket fees, with motions for lead plaintiff due by October 14, 2025.